Costco has a quiet public relations strategy that keeps it in the news without generating controversy. First, the chain never tells members exactly when it plans to raise the cost of a membership. It generally does that every five years, but its most recent increase happened seven years and two months after its previous price
Gold hit an all-time high near $5,600 an ounce in late January. It’s been sliding pretty much nonstop since then, and on June 19 the bank most responsible for hyping that rally finally caught up to where the price actually is. Goldman Sachs cut its year-end gold target by $500, down to $4,900 from $5,400.
Cathie Wood, chief of Ark Investment Management, is no stranger to buying into momentum. That’s what she did in the past week, initiating a position in a tech stock that has rallied more than 40% over the past month. In 2025, the flagship Ark Innovation ETF gained 35.49%, far outpacing the S&P 500’s return of
SpaceX (SPCX) stock slid for two straight sessions before Thursday’s close, dropping from a post-IPO high of $225.64 to $185.00. Then a top Wall Street analyst made one of the boldest calls yet on the stock. Arete Research initiated coverage of SpaceX on June 18 with a Buy rating and a price target of $401
AbbVie (ABBV) is closing in on a deal to buy Apogee Therapeutics for $10.9 billion in cash, according to a Reuters report citing people familiar with the matter in the Financial Times. The price values Apogee at a roughly 60% premium to its closing share price on Thursday, June 18, a steep markup for a
Google DeepMind is treating its most advanced AI agents the same way a security team treats an employee with sensitive access: as a potential insider threat. The company published an AI Control Roadmap on June 18 that assumes, for planning purposes, that a capable agent could try to evade oversight, copy itself without authorization, or
Building a retirement strategy often involves years of careful planning, consistent contributions, and ongoing portfolio management. But Vanguard is raising a concern that most investors overlook, and it’s one that has nothing to do with market returns or allocation strategy. Illness, a serious accident, or cognitive decline can strip an investor of decision-making ability at
Morgan Housel has sold 12 million books telling people that investing success comes down to behavior more than analysis. So when he sat down recently to talk about AI, you’d figure he’d lead with valuations or whether we’re in a bubble. He didn’t. He opened with a warning about the people actually building the stuff.
Three days. That’s how long the peace deal Trump and Iranian President Masoud Pezeshkian signed on June 17 lasted before Iran’s military command said it was closing the Strait of Hormuz again. Iran also sent a negotiating team to Switzerland at basically the same time, which is its own kind of confusing, Seeking Alpha reported.
President Donald Trump has been trading health care stocks unusually frequently in 2026. Across the first three months of the year, his accounts ran 377 separate health care trades, a mix of buys and sells, worth at least $13 million and as much as $37 million by the disclosed ranges. That activity sits inside a